Table 2.
Chemokines and inhibitory strategies in experimental CKD studies.
| Chemokine/ Chemokine Receptor |
Inhibitory Strategy | Species (Mice or Rats) | CKD Type | Beneficial Effects | Reference |
|---|---|---|---|---|---|
| MCP-1/ CCL2 |
Blocking of MCP-1 by injecting antisense oligodeoxynucleotide | Rats | Two months model of Goodpasteur syndrome. | ↓ MCP-1 mRNA. ↓ Mononuclear cell infiltration. ↓ Monocity/macrophages in the interstitium. ↓ Tubulointerstitial damage. |
[272] |
| CCL8 | Anti-CCL8 mAb | Mice | UUO mouse model (14 days). End-stage CKD in the obstructed kidney. | ↓ Fibrosis and apoptosis. ↓ E-cadherin and BCL-2. ↓ Fibronectin. ↓ CCR2. |
[50] |
| CXCL10/ IP-10 |
Inhibition by anti-IP-10/CXCL10 antibody | Rats | Rat model of renal endothelial microvascular injury in CKD. | ↓ Tubulointerstitial T cell recruitment. Improved renal function. ↓ Serum creatinine. ↓ BUN. |
[273] |
Abbreviations: MCP-1: monocyte chemoattractant protein-1, mAb: monoclonal antibody, mRNA: messenger ribonucleic acid, BCL-2: B-cell lymphoma 2, BUN: blood urea nitrogen, CCR2: C-C chemokine receptor 2, CKD: chronic kidney disease, UUO: unilateral ureteral obstruction, CCL2: C-C motif ligand 2, CCL8: C-C motif chemokine 8. Symbols: ↓ decrease.